Entinostat is a new drug for the treatment of reoccurring HR+ breast cancer in postmenopausal women and men. Studies on entinostat have suggested when combined with regular hormone therapy, it may lengthen survival time and slow the progression of the breast cancer.If entinostat is licenced in the UK, it could provide a new treatment option for patients with reoccurring HR+ breast cancer, which may extend patients’ survival time.
Entinostat for Hormone Refractory, HR+ Breast Cancer in Men and Postmenopausal Women
Interventions:
Entinostat (SNDX-275; RG7746)
Indications:
Breast cancer
Therapeutic Areas:
Breast Cancer
Year:
2017